BLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECVAYLI (teclistamab-cqyv) is a bispecific antibody therapeutic approved by the FDA in October 2022 as an injectable biologic. It is designed to engage dual targets to redirect immune cells against malignant cells, representing a novel mechanism in immuno-oncology. The drug is currently at peak lifecycle stage, indicating active commercial expansion and market establishment.
$0.29BPart D
PeakGrowing
Early peak-stage product with modest claims volume suggests growing oncology franchise requiring expansion of commercial and medical affairs teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Johnson & Johnson is hiring 2 roles related to this product
Worked on TECVAYLI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.